Evotec SE Comments on Withdrawal of Halozyme's Offer

Evotec SE, a company listed on the Frankfurt Stock Exchange and Nasdaq, has acknowledged the withdrawal of a non-binding acquisition proposal from Halozyme Therapeutics Inc. Initially offered at EUR11.00 per share in cash, the proposal was retracted on November 22, 2024.

The Management Board and Supervisory Board of Evotec, along with their advisors, were in the process of evaluating this proposal, which was initially suggested in a letter by Halozyme on November 13, 2024. The letter expressed interest in a strategic combination of the two companies.

Despite this development, Evotec's leadership remains committed to its independent growth strategy. The company believes this approach will enhance long-term profitability and provide substantial value to its shareholders.